Subtopic Deep Dive

mTORC2 and AKT Feedback Loops
Research Guide

What is mTORC2 and AKT Feedback Loops?

mTORC2 and AKT feedback loops refer to the bidirectional regulatory interactions where mTORC2 phosphorylates AKT at Ser473 to activate it, while activated AKT promotes mTORC2 assembly, creating positive feedback that sustains PI3K/AKT/mTOR signaling in cancer cells.

mTORC2 integrates growth signals to phosphorylate AKT-Ser473, essential for full AKT activation and cytoskeletal regulation (Laplante and Sabatini, 2009; 2102 citations). Feedback loops amplify this pathway, leading to rapalog resistance observed in clinical trials (Zoncu et al., 2010; 3909 citations). Over 20 papers detail Rictor-dependent mechanisms and dual inhibitor strategies.

Curated Papers

Key Challenges

Why It Matters

mTORC2-AKT loops drive resistance to rapamycin analogs in cancers like renal cell carcinoma, as PI3K/AKT/mTOR hyperactivation sustains tumor growth despite mTORC1 inhibition (Porta et al., 2014; 1437 citations). Dual PI3K/mTOR inhibitors like BEZ235 overcome this feedback, improving progression-free survival in preclinical models (Thoreen et al., 2009; 1778 citations). Targeting these loops enhances efficacy of AKT inhibitors in breast and prostate cancers (Glaviano et al., 2023; 1583 citations).

Key Research Challenges

Rapalog Resistance Mechanisms

mTORC1 inhibition by rapalogs activates AKT via mTORC2 feedback, limiting efficacy in solid tumors (Zoncu et al., 2010). Rictor knockout studies reveal persistent AKT phosphorylation through IGF-1R/PDK1 bypass (Laplante and Sabatini, 2009).

Dual Inhibitor Toxicity

ATP-competitive mTOR inhibitors like PP242 block both complexes but cause hyperglycemia and immunosuppression in trials (Thoreen et al., 2009). Balancing pathway inhibition with tolerability remains unresolved (Glaviano et al., 2023).

Feedback Loop Heterogeneity

Tumor-specific variations in Rictor expression alter loop dynamics across cancer types (Porta et al., 2014). Single-cell analyses are needed to map patient-specific feedback (Zoncu et al., 2010).

Essential Papers

mTOR: from growth signal integration to cancer, diabetes and ageing

Roberto Zoncu, Alejo Efeyan, David M. Sabatini · 2010 · Nature Reviews Molecular Cell Biology · 3.9K citations

mTOR signaling at a glance

Mathieu Laplante, David M. Sabatini · 2009 · Journal of Cell Science · 2.1K citations

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and su...

mTOR: a pharmacologic target for autophagy regulation

Young Chul Kim, Kun‐Liang Guan · 2015 · Journal of Clinical Investigation · 2.0K citations

mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregul...

A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB

Carmine Settembre, Roberto Zoncu, Diego L. Medina et al. · 2012 · The EMBO Journal · 1.9K citations

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Carson C. Thoreen, Seong A. Kang, Jae Won Chang et al. · 2009 · Journal of Biological Chemistry · 1.8K citations

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam et al. · 2023 · Molecular Cancer · 1.6K citations

Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth...

Targeting PI3K/Akt signal transduction for cancer therapy

Yan He, Miao Sun, Guo Geng Zhang et al. · 2021 · Signal Transduction and Targeted Therapy · 1.6K citations

Reading Guide

Foundational Papers

Start with Zoncu et al. (2010; 3909 citations) for mTOR signal integration overview, then Laplante and Sabatini (2009; 2102 citations) for pathway diagram, followed by Thoreen et al. (2009) for rapalog-resistant functions.

Recent Advances

Glaviano et al. (2023; 1583 citations) summarizes targeted therapies; He et al. (2021; 1575 citations) details PI3K/AKT transduction advances.

Core Methods

Rictor/Sin1 knockdown via siRNA/CRISPR; phospho-AKT Ser473 Western blots; PP242 or AZD8055 for dual inhibition; xenograft models for feedback validation (Thoreen et al., 2009).

How PapersFlow Helps You Research mTORC2 and AKT Feedback Loops

Discover & Search

Research Agent uses citationGraph on Zoncu et al. (2010) to map 3909 citing papers linking mTORC2 to AKT feedback in cancer, then exaSearch for 'mTORC2 Rictor knockout AKT Ser473 cancer' retrieves 50+ targeted results including Glaviano et al. (2023).

Analyze & Verify

Analysis Agent runs readPaperContent on Thoreen et al. (2009) to extract PP242 inhibition data, verifies AKT phosphorylation claims via verifyResponse (CoVe) against Laplante and Sabatini (2009), and uses runPythonAnalysis for statistical comparison of rapalog resistance curves with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in dual inhibitor trials via contradiction flagging across Porta et al. (2014) and Glaviano et al. (2023), while Writing Agent applies latexEditText and latexSyncCitations to generate a review section, using latexCompile for figure-ready output and exportMermaid for feedback loop diagrams.

Use Cases

"Extract and plot mTORC2-AKT phosphorylation data from rapalog resistance studies"

Research Agent → searchPapers('mTORC2 AKT Ser473 rapalog') → Analysis Agent → readPaperContent(Thoreen 2009) → runPythonAnalysis(pandas plot of p-AKT levels vs. dose) → matplotlib graph of feedback activation.

"Write LaTeX figure caption and cite mTORC2 feedback loop papers"

Synthesis Agent → gap detection(Zoncu 2010 + Laplante 2009) → Writing Agent → latexEditText('diagram caption') → latexSyncCitations(5 papers) → latexCompile → PDF-ready figure with feedback loop.

"Find GitHub repos analyzing mTORC2 knockout RNA-seq data"

Research Agent → searchPapers('Rictor knockout cancer') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → downloadable analysis scripts for AKT feedback datasets.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(250+ PI3K/mTOR hits) → citationGraph → DeepScan(7-step verify on feedback claims) → structured report with Rictor phenotypes. Theorizer generates hypotheses on dual inhibitor synergies from Glaviano et al. (2023) + Thoreen et al. (2009). DeepScan applies CoVe checkpoints to validate mTORC2-AKT loop models across 20 papers.

Try Doxa for mTORC2 and AKT Feedback Loops Research

Frequently Asked Questions

What defines mTORC2-AKT feedback loops?

mTORC2 phosphorylates AKT-Ser473 for activation, while AKT enhances mTORC2 via Sin1 phosphorylation, forming positive feedback that resists rapalogs (Laplante and Sabatini, 2009).

What methods study these loops?

Rictor knockout mice, CRISPR in cancer cell lines, and ATP-competitive inhibitors like PP242 reveal feedback (Thoreen et al., 2009; Zoncu et al., 2010).

What are key papers?

Zoncu et al. (2010; 3909 citations) reviews mTOR integration; Laplante and Sabatini (2009; 2102 citations) details signaling; Glaviano et al. (2023; 1583 citations) covers cancer therapies.

What open problems exist?

Heterogeneous feedback in patient tumors requires single-cell profiling; optimal dual inhibitor combinations lack phase III data (Porta et al., 2014; Glaviano et al., 2023).